The new initiative seeks to reduce inefficiencies and improve review times across all FDA centers by the end of next month.
The U.S. Food and Drug Administration (FDA) recently announced it will deploy generative artificial intelligence (AI) across all its centers by June 30, following a successful pilot program that significantly reduced the time needed for scientific reviews. The AI system will integrate with the FDA’s internal data platforms and operate on a secure, agency-wide infrastructure.
“I was blown away by the success of our first AI-assisted scientific review pilot. We need to value our scientists’ time and reduce the amount of non-productive busywork that has historically consumed much of the review process. The agency-wide deployment of these capabilities holds tremendous promise in accelerating the review time for new therapies,” said FDA Commissioner Marty Makary.
The FDA is requiring all centers to begin deploying the technology immediately. The rollout, overseen by Chief AI Officer Jeremy Walsh and the Center for Drug Evaluation and Research’s Office of Strategic Programs Director Sridhar Mantha, will include improvements tailored to the unique needs of each center, with a focus on ease of use, data integration, and compliance.
As the Lord Leads, Pray with Us…
- For Chief Officer Jeremy Walsh as he oversees the use of artificial intelligence in the FDA.
- For Director Mantha as he heads the Office of Strategic Programs in the Center for Drug Evaluation and Research.
- For wisdom for HHS and FDA officials as they implement artificial intelligence to streamline research and make more efficient use of researchers’ efforts.
Sources: Food and Drug Administration
